BeOne Medicines (NASDAQ:ONC) Insider Titus Ball Sells 169 Shares

by · The Markets Daily

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) insider Titus Ball sold 169 shares of the stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $257.20, for a total value of $43,466.80. Following the completion of the transaction, the insider owned 99,645 shares of the company’s stock, valued at $25,628,694. This trade represents a 0.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Trading Up 1.4%

ONC traded up $3.72 during trading on Monday, reaching $268.20. The company had a trading volume of 351,440 shares, compared to its average volume of 258,341. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. BeOne Medicines Ltd. – Sponsored ADR has a 12-month low of $239.25 and a 12-month high of $385.22. The company has a market cap of $29.43 billion, a price-to-earnings ratio of 60.00 and a beta of 0.49. The firm’s 50-day simple moving average is $298.56 and its 200 day simple moving average is $314.03.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last announced its earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The company had revenue of $1.51 billion during the quarter. Equities research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. EFG International AG bought a new stake in shares of BeOne Medicines in the 4th quarter valued at approximately $25,000. Leonteq Securities AG bought a new position in BeOne Medicines during the fourth quarter valued at approximately $35,000. Daiwa Securities Group Inc. acquired a new stake in BeOne Medicines in the second quarter valued at approximately $35,000. CWM LLC lifted its stake in BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after acquiring an additional 39 shares during the last quarter. Finally, Group One Trading LLC bought a new stake in BeOne Medicines in the fourth quarter worth approximately $61,000. 48.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Jefferies Financial Group downgraded shares of BeOne Medicines from a “buy” rating to a “hold” rating and cut their target price for the company from $420.00 to $290.00 in a research note on Monday, March 16th. Truist Financial reiterated a “buy” rating and set a $413.00 price target (up from $411.00) on shares of BeOne Medicines in a report on Thursday, May 7th. Leerink Partners lifted their price target on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Morgan Stanley restated an “overweight” rating and set a $395.00 price objective on shares of BeOne Medicines in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $390.00.

Read Our Latest Stock Report on BeOne Medicines

About BeOne Medicines

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Recommended Stories